CryoPort Inc CYRX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$19.10 up $3.05, 19.00% at close Nov 6
Last close · Previous close $16.05
- Market cap
- $962.68MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.91Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$19.10up $3.05, 19.00%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$16.05Nov 5
- Volume2.59MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.04MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $7.61 to $19.53; now $19.10
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CYRX beat the S&P 500 in 6 of 7 periods.
| Period | CYRX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CYRX: up 7.3% S&P 500: down 5.6% | CYRX beat the S&P 500 by 12.9 percentage points Beat |
| 3M | CYRX: up 29.8% S&P 500: down 4.1% | CYRX beat the S&P 500 by 33.9 percentage points Beat |
| YTD | CYRX: up 99.0% S&P 500: up 8.7% | CYRX beat the S&P 500 by 90.3 percentage points Beat |
| 1Y | CYRX: up 129.3% S&P 500: up 10.9% | CYRX beat the S&P 500 by 118.4 percentage points Beat |
| Long term | ||
| 3Y | CYRX: up 93.3% S&P 500: up 75.0% +24.6% vs +20.5% a year | CYRX beat the S&P 500 by 18.3 percentage points Beat |
| 5Y | CYRX: down 76.5% S&P 500: up 67.8% −25.1% vs +10.9% a year | CYRX trailed the S&P 500 by 144.3 percentage points Trailed |
| 10Y | CYRX: up 768.2% S&P 500: up 313.1% +24.1% vs +15.2% a year | CYRX beat the S&P 500 by 455.1 percentage points Beat |
$10,000 invested in CYRX 10 years ago (Nov 4, 2016) would be worth about $86,818 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
CYRX beat the S&P 500 in 6 of 7 periods.
| Period | CYRX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CYRX: up 7.3% S&P 500: down 5.6% | CYRX beat the S&P 500 by 12.9 percentage points Beat |
| 3M | CYRX: up 29.8% S&P 500: down 4.3% | CYRX beat the S&P 500 by 34.1 percentage points Beat |
| YTD | CYRX: up 99.0% S&P 500: up 7.8% | CYRX beat the S&P 500 by 91.2 percentage points Beat |
| 1Y | CYRX: up 129.3% S&P 500: up 9.7% | CYRX beat the S&P 500 by 119.6 percentage points Beat |
| Long term | ||
| 3Y | CYRX: up 93.3% S&P 500: up 68.8% +24.6% vs +19.1% a year | CYRX beat the S&P 500 by 24.5 percentage points Beat |
| 5Y | CYRX: down 76.5% S&P 500: up 56.9% −25.1% vs +9.4% a year | CYRX trailed the S&P 500 by 133.4 percentage points Trailed |
| 10Y | CYRX: up 768.2% S&P 500: up 252.6% +24.1% vs +13.4% a year | CYRX beat the S&P 500 by 515.6 percentage points Beat |
$10,000 invested in CYRX 10 years ago (Nov 4, 2016) would be worth about $86,818 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$113.95
Closing high on . Now 83.2% below that record.
Split-adjusted daily closes since Jan 2, 2009.
Stock splits
2
Latest: 1-for-12 on . Share counts adjust after each split.
Both splits
- 1-for-12
- 1-for-10
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.91 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. When CYRX was profitable over the past five years, its P/E ranged from 4.7× to 11.5×, with a median of 7.0×. How to read P/E
Other valuation measures
- 5.2×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 2.0×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −2.10%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $795.97MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CYRX DCF in Excel. Value CryoPort with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $186.45Mup 12.1%
- Net income
- −$37.39M
- Diluted EPS
- −$0.91
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $38.32M | $805.00K | −$0.02 |
| Q4 FY24 (Dec 31, 2024) | $41.45M | −$18.68M | −$0.42 |
| Q1 FY25 (Mar 31, 2025) | $41.04M | −$11.98M | −$0.28 |
| Q2 FY25 (Jun 30, 2025) | $45.45M | $108.87M | $2.13 |
| Q3 FY25 (Sep 30, 2025) | $44.23M | −$6.94M | −$0.18 |
| Q4 FY25 (Dec 31, 2025) | $45.45M | −$11.64M | −$0.28 |
| Q1 FY26 (Mar 31, 2026) | $47.80M | −$10.54M | −$0.25 |
| Q2 FY26 (Jun 30, 2026) | $48.97M | −$8.26M | −$0.20 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $222.61M | −$275.53M | −$6.18 |
| FY22 (Dec 31, 2022) | $237.28M | −$37.33M | −$0.93 |
| FY23 (Dec 31, 2023) | $168.66M | −$99.59M | −$2.21 |
| FY24 (Dec 31, 2024) | $156.77M | −$114.76M | −$2.49 |
| FY25 (Dec 31, 2025) | $176.18M | $78.30M | $1.40 |
Margins
- Gross 47.1%
- Operating −21.2%
- Net −20.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$20.18MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$7.97MLast 12 months
- Capital spending$28.16MLast 12 months
- −10.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $3.70MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$3.70MLast 12 months
Balance sheet
- $398.73MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$232.02MAs of Jun 30, 2026
- Net cash$166.71MAs of Jun 30, 2026
- 2.08As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.47As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −7.5%Last 12 months
Over the last 12 months, CryoPort lost money: its net loss was 7.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −4.9%Last 12 months
Over the last 12 months, CryoPort’s net loss was 4.9% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About CryoPort Inc
CryoPort, Inc. provides frozen logistics solutions to the life sciences industry in the United States, Europe, Asia, and internationally. The company offers Cryoportal, a cloud-based logistics management software that automates the entry of orders, prepares customs documentation, and facilitates status and location monitoring of shipped orders while in transit; and CryoPort Express Shippers, which are dry cryogenic shippers that use liquid nitrogen contained inside a vacuum insulated bottle, which serves as a refrigerant to provide stable storage temperatures. It also provides Cryoport Express Standard Shippers, which are re-usable dry vapor liquid nitrogen storage containers for holding the biological material in the inner chamber; CryoPort Express High Volume Shippers, which use a dry vapor liquid nitrogen technology to maintain temperatures; and CryoPort Express Smart Pak, a self-contained automated data logger, which records cryogenic temperatures of samples shipped in CryoPort Express Shippers. In addition, the company offers CryoPort Express Analytics, which reports shipment performance metrics, and evaluates temperature-monitoring data collected by the data logger during shipment, as well as biological material holders that are containment bags used in connection with the shipment of infectious or dangerous goods using the CryoPort Express Shippers. CryoPort, Inc. has a strategic alliance with Liventa Bioscience, Inc. The company was founded in 1999 and is based in Lake Forest, California.
- Sector
- Industrials
- Industry
- Integrated Freight & Logistics
- Headquarters
- Tennessee, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CYRX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CYRX stock FAQ
What is CYRX stock’s price today?
CryoPort (CYRX) traded at $19.10 at the close on , up $3.05 (19.00%) from the previous close of $16.05. Over the past 52 weeks it has traded between $7.61 and $19.53.
If you invested $1,000 in CYRX 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CYRX on would be worth about $8,682 at the close on , a total return of +768.2%. The same $1,000 would be worth $235 if invested five years ago and $2,293 if invested one year ago. Past performance doesn’t predict future returns.
What is CryoPort’s market cap?
CryoPort’s market capitalization is about $962.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $19.10 (how market cap works). CryoPort reported 50.40M shares outstanding at the end of its latest quarter ().
What is CYRX’s P/E ratio?
CYRX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.91). When it was profitable over the past five years, its P/E ranged from 4.7 to 11.5.
How much revenue does CryoPort make?
CryoPort reported $186.5 million of revenue over the four quarters to , up 12.1% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $49.0 million, up 7.7% from a year earlier.
Is CryoPort profitable?
Not over the four quarters to . CryoPort reported a net loss of $37.4 million across those four quarters on $186.5 million of revenue.
What are CYRX’s earnings per share?
CYRX’s diluted earnings per share were −$0.91 over the four quarters to , compared with $1.41 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.20 per share, against $2.13 a year earlier (how EPS works).
Does CYRX pay a dividend?
CryoPort hasn’t paid a dividend in the last twelve months.
What is CYRX’s 52-week high and low?
Over the past 52 weeks CYRX has traded as low as $7.61 and as high as $19.53. At $19.10 at the close on , it is 2.2% below that high and 151.0% above the low.
What is CYRX’s all-time high?
CYRX’s highest closing price was $113.95 on , adjusted for stock splits. At $19.10 at the close on , it is 83.2% below that record.
Has CYRX stock ever split?
Yes, twice: 1-for-10 on ; 1-for-12 on .
How has CYRX stock performed?
Including dividends and measured to the close on , CYRX has returned +99.0% so far this year and +129.3% over the past year, and −76.5% over five years (−25.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is CryoPort in?
CryoPort is in the Industrials sector and the Integrated Freight & Logistics industry, and is headquartered in Tennessee, USA.
What exchange does CYRX trade on?
CryoPort trades on the Nasdaq under the ticker symbol CYRX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.